Seer, Inc.

NMS: SEER
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Seer, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get SEER Z-Score →

About Seer, Inc.

Healthcare Biotechnology
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

📊 Fundamental Analysis

Seer, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.

The company recently reported 5.0% revenue growth, which is modest compared to its industry peers.

Return on Equity (ROE) is -25.1%, which indicates that capital utilization is currently under pressure.

At a current price of $1.69, SEER currently trades near the bottom of its 52-week range (5%), indicating potential value or weakness (Range: $1.65 - $2.41).

🏥 Financial Health

🔴 Profit Margin Weak
Debt/Equity Excellent
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
🔴 Beta (Risk) High Volatility

Key Financials

Market Cap
$95.35M
Trailing P/E
--
Forward P/E
-1.61
Beta (5Y)
1.60
52W High
$2.41
52W Low
$1.65
Avg Volume
266K
Day High
Day Low
Get SEER Z-Score on Dashboard 🚀